<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60575">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143635</url>
  </required_header>
  <id_info>
    <org_study_id>CHDM201X2101</org_study_id>
    <nct_id>NCT02143635</nct_id>
  </id_info>
  <brief_title>Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt</brief_title>
  <official_title>A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: National Agency for the Safety of Medicine and Health Products</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices (BfArM)</authority>
    <authority>The Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Spain: Medicines and Health Products Agency (AEMPS)</authority>
    <authority>Singapore: Health Sciences Authority (HSA)</authority>
    <authority>Taiwan: Center for Drug Evaluation</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency (PMDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with
      selected advanced tumors characterized by wild-type TP53.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>up to 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>DLTs in the first cycle of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events  (AEs)</measure>
    <time_frame>For the duration of treatment, an average of 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with AEs as a measure of Safety and tolerability of HDM201 single agent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters of HDM201</measure>
    <time_frame>Up to 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of Pharmacodynamics markers</measure>
    <time_frame>Baseline, up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every 8 weeks (for solid tumors), every cycle (for hematological tumors) until end of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>end of treatment = 1 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Advanced Solid and Hematological TP53wt Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a TP53wt locally advanced or metastatic solid malignancy and with
             measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1
             criteria.

          -  Patients with the TP53wt hematological tumors (AML, ALL, HR-MDS) who have failed
             prior therapies or who are considered inappropriate candidates for standard induction
             therapy.

        Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Prior treatment with compounds with the same mode of action

          -  Subjects with significant or uncontrolled cardiovascular disease

          -  History of thromboembolic or cerebrovascular events within the last 6 months,
             including transient ischemic attack, cerebrovascular accident, deep vein thrombosis,
             or pulmonary embolism

          -  Previous and concomitant therapy that precludes enrollment, as defined in the
             protocol

          -  Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or
             Hepatitis C infection

          -  Patients who have undergone major surgery within the 2 weeks prior to starting study
             treatment or who have not fully recovered from previous surgery

          -  Women of child-bearing potential, unless they are using highly effective methods of
             contraception during dosing and for 2 weeks after study drug discontinuation

          -  Pregnant or nursing women

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Onc. Dep</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nana Akom</last_name>
      <phone>646-888-4426</phone>
      <email>akomn@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>David Hyman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>WÃ¼rzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan ROC</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDM201,TP53wt, p53, MDM2, HDM2, advanced tumors, BLRM (Bayesian logistic regression model)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Li-Fraumeni Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
